ResultsIQ

ResultsIQ › Latest results › Poly Medicure Limited

Poly Medicure Limited Q3 FY26 earnings call summary

NSE: POLYMED · BSE: 531768

Earnings call of 6 Feb 2026, summarised by AI from the filing.

PendraCare and Citieffe consolidated in Q3, adding ₹48-49 cr to top line; full-year impact in FY27.

Key takeaways

  1. Acquisitions PendraCare and Citieffe consolidated in Q3, adding ₹48-49 cr to top line; full-year impact in FY27.
  2. China dumping Chinese suppliers dumping and cutting prices in global markets, pressuring regional business growth.

Original filing on BSE

Poly Medicure Limited Q1 FY27 results

As filed: Revenue ₹525 cr (+30% year on year), EBITDA ₹125 cr (+18% year on year), PAT ₹85.3 cr (−8% year on year), EBITDA margin 23.8% (−249 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹535 cr (+21% year on year), EBITDA ₹110 cr (−8% year on year), PAT ₹65.0 cr (−29% year on year), EBITDA margin 20.7% (−656 bps). Score 32 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 656 bps year on year. Profit fell 8% from last quarter. Revenue rose ₹93.5 cr on a year ago, more than the ₹63.0 cr it added the year before. Share price after the results: +6.7% in 30 days (Nifty 500: +0.9%).
  • Q3 FY26: Revenue ₹494 cr (+16% year on year), EBITDA ₹111 cr (−3% year on year), PAT ₹70.8 cr (−17% year on year), EBITDA margin 22.5% (−460 bps). Score 14 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 460 bps year on year. Other income 27% of PBT. Profit fell 23% from last quarter. Profit rose ₹-14.2 cr on a year ago, against ₹20.0 cr the year before. Share price after the results: −10.6% in 29 days (Nifty 500: −4.5%).
  • Q2 FY26: Revenue ₹444 cr (+6% year on year), EBITDA ₹115 cr (0% year on year), PAT ₹92.0 cr (+6% year on year), EBITDA margin 25.9% (−148 bps). Score 9 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 148 bps year on year. Other income 28% of PBT. Revenue rose ₹24.0 cr on a year ago, against ₹83.0 cr the year before. Share price after the results: −1.9% in 30 days (Nifty 500: 0.0%).
  • Q1 FY26: Revenue ₹403 cr (+5% year on year), EBITDA ₹106 cr (+2% year on year), PAT ₹93.0 cr (+26% year on year), EBITDA margin 26.3% (−71 bps). Score 27 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was in line with it. EBITDA margin fell 71 bps year on year. Other income 34% of PBT. Revenue fell 9% from last quarter. Revenue rose ₹18.0 cr on a year ago, against ₹64.0 cr the year before. Share price after the results: +5.5% in 28 days (Nifty 500: +0.6%).
  • Q4 FY25: Revenue ₹441 cr (+17% year on year), EBITDA ₹120 cr (+25% year on year), PAT ₹92.0 cr (+35% year on year), EBITDA margin 27.2% (+181 bps). Score 70 of 100, Above trend. Revenue growth was well below the company's own trend; EBITDA growth was in line with it; profit growth was above it. EBITDA margin rose 181 bps year on year. Revenue rose ₹63.0 cr on a year ago, against ₹71.0 cr the year before. Share price after the results: −19.6% in 30 days (Nifty 500: +4.5%).
  • Q3 FY25: Revenue ₹424 cr (+25% year on year), EBITDA ₹115 cr (+29% year on year), PAT ₹85.0 cr (+31% year on year), EBITDA margin 27.1% (+95 bps). Score 69 of 100, Above trend. Revenue, EBITDA and profit growth were above the company's own trend. EBITDA margin rose 95 bps year on year. Revenue rose ₹84.0 cr on a year ago, more than the ₹55.0 cr it added the year before.
  • Q2 FY25: Revenue ₹420 cr (+25% year on year), EBITDA ₹115 cr (+37% year on year), PAT ₹87.0 cr (+40% year on year), EBITDA margin 27.4% (+246 bps). Score 81 of 100, Above trend. EBITDA margin rose 246 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Poly Medicure Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.